Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies

Codolo, Gaia, Plotegher, Nicoletta, Pozzobon, Tommaso, Brucale, Marco, Tessari, Isabella, Bubacco, Luigi, de Bernard, Marina·2013·PLoS ONE
DOI 10.1371/journal.pone.0055375

Cited by (587)

Items 401–500 of 587

  1. Critical Contribution of Adenosine A2AReceptors in Bone Marrow–Derived Cells to White Matter Lesions Induced by Chronic Cerebral Hypoperfusion
    Hong Ran, Wei Duan, Zili Gong, Senlin Xu, He Zhu, Xianhua Hou, Li Jiang, Qifen He, Jian Zheng · 2015 · Journal of Neuropathology & Experimental Neurology
  2. The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson’s disease
    Yan Shen, Xingfang Guo, Chao Han, Fang Jung Wan, Kai Ma, Shiyi Guo, Luxi Wang, Yun Fei Xia, Ling Liu, Zhicheng Lin et al. · 2017 · Cellular and Molecular Life Sciences
  3. Molecular crosstalk between circadian clock and NLRP3 inflammasome signaling in Parkinson's disease
    Jiahua Huang, Wenwei Li · 2024 · Heliyon
  4. Lack of genetic evidence for NLRP3 inflammasome involvement in Parkinson’s disease pathogenesis
    Konstantin A. Senkevich, Lang Liu, Chelsea X. Alvarado, Hampton L. Leonard, Mike A. Nalls, Global Parkinson’s Genetics Program (GP2), Ziv Gan‐Or · 2024 · npj Parkinson s Disease
  5. Defining (and blocking) neuronal death in Parkinson’s disease: Does it matter what we call it?
    Anna Memou, Lampros Dimitrakopoulos, Maria Kedariti, Michalis Kentros, Andriana Lamprou, Lilian Petropoulou-Vathi, Polytimi‐Eleni Valkimadi, Hardy J. Rideout · 2021 · Brain Research
  6. Synucleinopathies Take Their Toll: Are TLRs a Way to Go?
    Gabriella Margherita Mazzotta, Nadia Ceccato, Carmela Conte · 2023 · Cells
  7. Les inflammasomes et les maladies humaines
    Yvan Jamilloux, Pascal Sève, Thomas Henry · 2014 · La Revue de Médecine Interne
  8. Inflammasome in drug abuse.
    Enquan Xu, Jianuo Liu, Xiaobei Wang, Huangui Xiong · 2017 · PubMed Central
  9. Multifaceted roles of extracellular vesicles in the interplay of neuroinflammation and neurodegenerative diseases
    Zhujie Deng, Haiyan Chen, Jiazhi Chen, Zhiyun Du, Wei Zhou, Zhengqiang Yuan · 2025 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  10. Elevated GRO-α and IL-18 in serum and brain implicate the NLRP3 inflammasome in frontotemporal dementia
    Hiu Chuen Lok, Jared S. Katzeff, John R. Hodges, Olivier Piguet, YuHong Fu, Glenda Margaret Halliday, Woojin Scott Kim · 2023 · Scientific Reports
  11. Altered vacuole membrane protein 1 (VMP1) expression is associated with increased NLRP3 inflammasome activation and mitochondrial dysfunction
    Stephanie R. Zack, Meghana Venkatesan, Roman M. Nikolaienko, Ben Cook, Ronald Melki, Aleksey V. Zima, Edward M. Campbell · 2024 · Inflammation Research
  12. Die hard: necroptosis and its impact on age-dependent neuroinflammatory diseases
    Kaitlan Smith, Meagan Colie, Trinity Moore, Jonathan Cummings Schisler · 2024 · Frontiers in Cell Death
  13. hCeO2@ Cu5.4O nanoparticle alleviates inflammatory responses by regulating the CTSB–NLRP3 signaling pathway
    Ying Li, Xiaomin Xia, Zhaojun Niu, Ke Wang, Jie Liu, Xue Li · 2024 · Frontiers in Immunology
  14. Overcoming challenges of clinical cell therapies for Parkinson's disease with photobiomodulation
    Hossein Chamkouri, Jianmin Si, Peng Chen, Haiyong Ni, Denis E. Bragin, Majid Ahmadlouydarab, Chaoshi Niu, Lei Chen · 2024 · Interdisciplinary medicine
  15. Parkinson’s disease models and death signaling: what do we know until now?
    Luiz Fernando A. T. Pedrão, Pâmela Medeiros, Estela C. Leandro, Bárbara Falquetto · 2024 · Frontiers in Neuroanatomy
  16. Effect of chemokine CC ligand 2 (CCL2) on α‑synuclein‑induced microglia proliferation and neuronal apoptosis
    Lijun Zhang, Pengju Ma, Qing-Kai Guan, Lei Meng, Linlin Su, Lina Wang, Bin Yuan · 2018 · Molecular Medicine Reports
  17. Buffering capacity is determinant for restoring early α-synuclein aggregation
    Marco A. Saraiva, Maria Helena Florêncio · 2022 · Biophysical Chemistry
  18. Celastrol Downmodulates Alpha-Synuclein-Specific T Cell Responses by Mediating Antigen Trafficking in Dendritic Cells
    Lam Ng, Xiaohui Wang, Chuanbin Yang, Cheng-Fu Su, Min Li, Allen Ka Loon Cheung · 2022 · Frontiers in Immunology
  19. GDF15 upregulation in Parkinson's disease: Compensatory mechanisms and causal insights
    Sultan Mohammed Alshahrani, Hayder Mutter Al-Kuraishy, Ali K. Albuhadily, Ali Ismail Al-Gareeb, Ahmed M Abdelaziz, Athanasios T. Alexiou, Marios Papadakis, Mubarak Alruwaili, Gaber El‐Saber Batiha · 2025 · Cytokine
  20. Spatiotemporal crosstalk among mitochondrial dynamics, NLRP3 inflammasome activation, and histone lactylation drives α-synuclein pathology in prodromal Parkinson’s disease
    Peng Lv, Xia Chen, Shiping Liu, Yu Zhang, Yan Bai, Shun Wang, Yulin Wang · 2025 · Frontiers in Cellular Neuroscience
  21. Toll‐like receptor 10 controls TLR2‐induced cytokine production in monocytes from patients with Parkinson's disease
    Hermínio Maurício da Rocha Sobrinho, Rodrigo Saar Gomes, Delson José da Silva, Valéria Bernadete Leite Quixabeira, Leo A. B. Joosten, Cristina Ribeiro de Barros Cardoso, Fátima Ribeiro‐Dias · 2021 · Journal of Neuroscience Research
  22. Immune responses to oligomeric α-synuclein in Parkinson’s disease peripheral blood mononuclear cells
    Ana Florencia Vega-Benedetti, Clara Porcedda, Tommaso Ercoli, Giuliana Fusco, Chiara Burgaletto, Rita Pillai, Francesca Palmas, Anna Flavia Cantone, Fabrizio Angius, Paolo Solla et al. · 2024 · Journal of Neurology
  23. C9orf72 dipeptides activate the NLRP3 inflammasome
    Jack Rivers‐Auty, Christopher Hoyle, Ayesha Pointer, Catherine B. Lawrence, Stuart M. Pickering-Brown, David Brough, Sarah Ryan · 2024 · Brain Communications
  24. New Insights on the Potential Role of Pyroptosis in Parkinson’s Neuropathology and Therapeutic Targeting of NLRP3 Inflammasome with Recent Advances in Nanoparticle-Based miRNA Therapeutics
    ‏Hebatallah M. Saad, Esraa A. Salem, Abeer E. Elsayed · 2025 · Molecular Neurobiology
  25. Ulinastatin inhibits NLRP3-induced apoptosis in a PD cell model
    Yicheng Lin, Dongsheng Xu, Feng Gao, Xiaolei Zheng · 2021 · Annals of Translational Medicine
  26. [Macrophage migration inhibitory factor meditates MPP+/MPTP-induced NLRP3 inflammasome activation in microglia cells].
    Heling Huang, Yuyuan Gao, Kun Nie, Li Wang · 2021 · PubMed Central
  27. Environmental neurotoxicants and inflammasome activation in Parkinson’s disease – A focus on the gut-brain axis
    Aishwarya Mary Johnson, Zhen-Yi Andy Ou, Richard Gordon, Hariharan Saminathan · 2021 · The International Journal of Biochemistry & Cell Biology
  28. A Novel Bibenzyl Compound (20C) Protects Mice from 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine/Probenecid Toxicity by Regulating the α-Synuclein–Related Inflammatory Response
    Qiu-Shuang Zhang, Yang Heng, Ying Chen, Piao Luo, Lu Wen, Zhao Zhang, Yu‐He Yuan, Nai‐Hong Chen · 2017 · Journal of Pharmacology and Experimental Therapeutics
  29. Targeting metabotropic glutamate receptors for symptomatic and disease-modifying treatment in Parkinson’s disease
    Marika Alborghetti, Alessia Ceccherelli, Matteo Caridi, Ferdinando Nicoletti, Giuseppe Battaglia, Valeria Bruno · 2025 · npj Parkinson s Disease
  30. Pharmacological Analysis of NLRP3 Inflammasome Inhibitor Sodium [(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl][(1-methyl-1H-pyrazol-4-yl)({[(2S)-oxolan-2-yl]methyl})sulfamoyl]azanide in Cellular and Mouse Models of Inflammation Provides a Translational Framework
    John R. Doedens, Pamela J. Smolak, MyTrang Nguyen, Heather Wescott, Christine Diamond, Ken Schooley, Andy Billinton, David Harrison, Beverly H. Koller, Alan P. Watt et al. · 2024 · ACS Pharmacology & Translational Science
  31. Imaging flow cytometry reveals LPS-induced changes to intracellular intensity and distribution of α-synuclein in a TLR4-dependent manner in STC-1 cells
    Anastazja M. Gorecki, Chidozie C. Anyaegbu, Melinda Fitzgerald, Kathryn A. Fuller, Ryan S. Anderton · 2024 · Methods
  32. Low levels of alpha-synuclein in peripheral tissues are related to clinical relapse in relapsing-remitting multiple sclerosis: a pilot cross-sectional study
    Manuel Mejía, Ildefonso Rodríguez‐Leyva, Fernando Cortés-Enríquez, Érika Chi-Ahumada, Diana Patricia Portales‐Pérez, Miguel Ángel Macías-Islas, María Esther Jiménez-Capdeville · 2018 · Journal of the Neurological Sciences
  33. Tissue-specific features of microglial innate immune responses
    Raissa Timmerman, Saskia Maria Burm, Jeffrey John Bajramovic · 2020 · Neurochemistry International
  34. Supramolecular organizing centers at the interface of inflammation and neurodegeneration
    Petra Sušjan, Taja Železnik Ramuta, Elvira Boršić, Sara Orehek, Iva Hafner‐Bratkovič · 2022 · Frontiers in Immunology
  35. On the Potential Therapeutic Roles of Taurine in Autism Spectrum Disorder
    Alberto Rubio‐Casillas, Elrashdy M Moustafa Mohamed Redwan, Vladimir Nikolaevich Uversky · 2022 · Neuroglia
  36. Transcriptional Analysis of Nuclear-Encoded Mitochondrial Genes in Eight Neurodegenerative Disorders: The Analysis of Seven Diseases in Reference to Friedreich’s Ataxia
    Muhammad Elsadany, Reem A. Elghaish, Aya S. Khalil, Alaa S. Ahmed, Rana H. Mansour, Eman Badr, Menattallah Elserafy · 2021 · Frontiers in Genetics
  37. Nanomedicines targeting the inflammasome as a promising therapeutic approach for cell senescence
    Swati Chaturvedi, Zaiba Naseem, Sherif F. El‐Khamisy, Muhammad Wahajuddin · 2022 · Seminars in Cancer Biology
  38. Indoleamine 2,3-dioxygenase (IDO1) – Can dendritic cells and monocytes expressing this moonlight enzyme change the phase of Parkinson’s Disease?
    Milene Gonçalves, Paulo Rodrigues‐Santos, Cristina Januário, Marco Cosentino, Frederico Costa Pereira · 2024 · International Immunopharmacology
  39. Nanoplatforms Targeting Intrinsically Disordered Protein Aggregation for Translational Neuroscience Applications
    Chih Hung Lo, Lenny Yi Tong Cheong, Jialiu Zeng · 2025 · Nanomaterials
  40. Exploring the Role of NLRP3 in Neurodegeneration: Cutting‐Edge Therapeutic Strategies and Inhibitors
    Mohammed Ahmed Mustafa, Pooja Bansal, MS Pallavi, Rajashree Panigrahi, Deepak Nathiya, Sachin Kumar, Shaker Al-Hasnaawei, Ashish Singh Chauhan, Siya Singla · 2025 · Developmental Neurobiology
  41. Low serum Α-SYNUCLEIN and oligomer Α-SYNUCLEIN levels in multiple sclerosis patients
    Nuray Bilge, Fatma Şimşek, Recep Yevgi, Mustafa Ceylan, Seda Aşkın · 2020 · Journal of Neuroimmunology
  42. Toxicity of extracellular alpha-synuclein is independent of intracellular alpha-synuclein
    Yanina Dening, Theresa Straßl, Viktoria Ruf, Petra Dirscherl, Alexandra Chovsepian, Aliçia Stiévenard, Amit Khairnar, Felix Schmidt, Florian Giesert, Jochen Wolfgang Herms et al. · 2022 · Scientific Reports
  43. A PARP-1 Feed-Forward Mechanism To Accelerate α-Synuclein Toxicity in Parkinson’s Disease
    Buyan Pan, E. James Petersson · 2019 · Biochemistry
  44. Platelet Behavior Contributes to Neuropathologies: A Focus on Alzheimer's and Parkinson's Disease
    Martin J. Page, Etheresia Pretorius · 2021 · Seminars in Thrombosis and Hemostasis
  45. Spatiotemporal proteomic profiling of cellular responses to NLRP3 agonists
    Louis Robert Hollingsworth, Priya Veeraraghavan, João A. Paulo, J. Wade Harper · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  46. Activation of NLRP3 Inflammasome by Virus-Like Particles of Human Polyomaviruses in Macrophages
    Asta Lučiūnaitė, Indrė Dalgėdienė, Rapolas Žilionis, Kristina Mašalaitė, Milda Norkienė, Andrius Šinkūnas, Alma Gedvilaitė, Indrė Kučinskaitė-Kodzė, Aurelija Žvirblienė · 2022 · Frontiers in Immunology
  47. Unveiling Parkinson’s disease through biomarker research: current insights and future prospects
    Nazlı Durmaz Çelik, Serkan Özben, Tomris Özben · 2024 · Critical Reviews in Clinical Laboratory Sciences
  48. Discovery of 2-(6-{[(1R,2R)-2-hydroxycyclohexyl]amino}-4,5-dimethylpyridazin-3-yl)-5-(trifluoromethyl)phenol (ASP0965): A potent, orally active and brain-penetrable NLRP3 inflammasome inhibitor with a novel scaffold for the treatment of α-synucleinopathy
    Yusuke Inagaki, Takashi Kamikubo, Ikumi Kuriwaki, Junko A. Watanabe, Susumu Yamaki, Maiko Iida, Kyoko Tomita, Kenichi Kakefuda, Jun Kurokawa, Tetsuo Kiso et al. · 2024 · Bioorganic & Medicinal Chemistry
  49. IC100 blocks inflammasome activation induced by α-synuclein aggregates and ASC specks
    Brianna St. Cyr, Regina Vontell, Roey Hadad, Juan Pablo de Rivero Vaccari, Robert W. Keane · 2025 · npj Parkinson s Disease
  50. Mechanism of NLRP3 inflammasome activation and its role in Alzheimer’s disease
    Xiaohan Gao, Xiaoxia Zhang, Yaxuan Sun, Xueling Dai · 2022 · Exploration of Immunology
  51. Disease mechanisms as subtypes: Microbiome
    Salvatore Bonvegna, Roberto Cilia · 2023 · Handbook of clinical neurology
  52. Coumarin-chalcone hybrid LM-021 and indole derivative NC009-1 targeting inflammation and oxidative stress to protect BE(2)-M17 cells against α-synuclein toxicity
    Pei-Ning Yang, Wanling Chen, Jun-Wei Lee, Chih‐Hsin Lin, Yi‐Ru Chen, Chung‐Yin Lin, Wenwei Lin, Ching‐Fa Yao, Yih‐Ru Wu, Kuo‐Hsuan Chang et al. · 2023 · Aging
  53. Neurodegeneration, Mitochondria, and Antibiotics
    Juan Miguel Suarez-Rivero, Juan López‐Pérez, Inés Muela‐Zarzuela, Carmen J. Pastor‐Maldonado, Paula Cilleros-Holgado, David Gómez-Fernández, Mónica Álvarez-Córdoba, Manuel Munuera-Cabeza, Marta Talaverón-Rey, Suleva Povea-Cabello et al. · 2023 · Metabolites
  54. Characterization of pSer129-αSyn Pathology and Neurofilament Light-Chain Release across In Vivo, Ex Vivo, and In Vitro Models of Pre-Formed-Fibril-Induced αSyn Aggregation
    Maja L. Hansen, Malene Ambjørn, Mikkel Nors Harndahl, Tau Benned‐Jensen, Karina Fog, Kaare Bjerregaard-Andersen, Florence Sotty · 2024 · Cells
  55. Alpha synuclein and inflammaging
    Geneviève L Putnam, Robert W. Maitta · 2025 · Heliyon
  56. DPP-4 inhibitor alleviates gut-brain axis pathology in Parkinson’s disease
    Seong Ho Jeong, Yeon Ju Kim, Jin Young Shin, Kyu Won Oh, Jung Wook Lee, Phil Hyu Lee · 2025 · Gut
  57. Evaluating the Impact of Thermal Processing on the Anti-Inflammatory Activity of Non-Centrifugal Cane Sugar: Implications on Cytokine Secretion and TLR4 Signaling
    Laura Rueda-Gensini, Julian A. Serna, Natalia I. Bolaños, Jader Rodríguez, Juan C. Cruz, Carolina Muñoz-Camargo · 2022 · Frontiers in Pharmacology
  58. A comparison of machine learning approaches for the quantification of microglial cells in the brain of mice, rats and non-human primates
    Danish Anwer, Francesco Gubinelli, Yunus A. Kurt, Livija Sarauskyte, Febe Jacobs, Chiara Venuti, Ivette M. Sandoval, Yiyi Yang, Jennifer A. Stancati, Martina Mazzocchi et al. · 2023 · PLoS ONE
  59. Neuroinflammation mediators are reduced in sera of Parkinson?s disease patients with mild cognitive impairment
    Ani Kıçık, Erdem Tüzün, Emel Erdoğdu, Başar Bılgıç, Zeynep Tüfekçıoğlu, Esin Öztürk-Işık, Haşmet Ayhan Hanağası, Hakan I. Gurvit · 2019 · Nöro Psikiyatri Arşivi
  60. New idea of Fuke Qianjin capsule in treating sequelae of pelvic inflammatory disease: Anti-inflammatory in the early stage and reparative in the later stage
    Chunfang Xu, Meijin Yi, Zhikui Xiao, Feng Xiang, Mengyao Wu, Zhimin Zhang, Yuanqing Zheng, Yun Gong, Yamei Li, Liang Su et al. · 2024 · Journal of Ethnopharmacology
  61. Protective Effects of Antcin H Isolated from Antrodia cinnamomea Against Neuroinflammation in Huntington’s Disease via NLRP3 Inflammasome Inhibition
    Yu‐Jun Chang, Cheng‐Hsu Chen, Yi‐Chen Chen, Ming-Tse Wu, Ting-Yu Lin, Kuo‐Feng Hua, Tz‐Chuen Ju · 2024 · Journal of Neuroimmune Pharmacology
  62. The role of Poly-ADP ribose polymerase (PARP) enzymes in chemotherapy-induced cognitive impairments – parallels with other neurodegenerative disorders
    Dahlia A. Ordaz, Kalpna Gupta, Daniela Annenelie Bota · 2025 · Frontiers in Pharmacology
  63. Emerging the role of trace minerals and vitamins in Alzheimer's disease
    Kamaljeet, Amandeep Kaur, Lovekesh Singh · 2024 · Brain Disorders
  64. Alpha-synuclein and RNA viruses: Exploring the neuronal nexus
    Anjali Gupta, Vijay Singh Bohara, Yeshavanth Banasavadi‐Siddegowda, Nitin Chaudhary, Sachin Kumar · 2024 · Virology
  65. Post‐inflammatory administration of N‐acetylcysteine reduces inflammation and alters receptor levels in a cellular model of Parkinson's disease
    Zeynep Bengisu Kaya, Elif Karakoç, Pamela J. McLean, Esen Saka, Pergin Atilla · 2023 · FASEB BioAdvances
  66. In Vitro Ameliorative Effects of Sinapic Acid on Parkinson Related Neurotoxicity in SHSY5Y Cell Lines
    Preeja Prabhakar, Abdul Bakrudeen Ali Ahmed, Saravana Babu Chidambaram, Arun Kumar, Arjun Pandian · 2023 · International journal of Nutrition Pharmacology Neurological Diseases
  67. Caspase 1 activity influences juvenile Batten disease ( CLN 3) pathogenesis
    Maria E. Burkovetskaya, Megan E. Bosch, Nikolay Karpuk, Rachel W. Fallet, Tammy Kielian · 2018 · Journal of Neurochemistry
  68. Biomaterials and Nanoparticle-Based Therapeutics in Neurodegenerative Diseases: Bridging the Gap Between Innovation and Translation
    Dia Panchal, Dattavi Solanki, Raghu Solanki, Amit K. Yadav, Dhiraj Devidas Bhatia, Pankaj Kumar Yadav · 2026 · ACS Chemical Neuroscience
  69. VCP Inhibition Augments NLRP3 Inflammasome Activation
    Ankita Sharma, Dhruva D. Dhavale, Paul T. Kotzbauer, Conrad Chris Weihl · 2024 · Inflammation
  70. A role of inflammasomes in the pathogenesis of neurological and mental diseases
    С.В. Пирожков, Natalia N. Terebilina, Peter F. Litvitskiy · 2018 · S S Korsakov Journal of Neurology and Psychiatry
  71. Proinflammatory profile in the skin of Parkinson’s disease patients with and without pain
    Joana Lama, Elena Salabasidou, Jens Volkmann, Anastasia Kuzkina, Susan Duty, Nurcan Üçeyler · 2022 · PLoS ONE
  72. Autophagy and Parkinsons Disease-Role of Caffeine as Autophagic Stimulator and Anti Apoptotic Agent
    Swathi Surendran, Geethu Suresh, Nithin Vijayakumar, Rajesh Ramachandran · 2023 · Nepal Journal of Biotechnology
  73. A review of studies on the implication of NLRP3 inflammasome for Parkinson’s disease and related candidate treatment targets
    Nannan Zeng, Qi Wang, Chong Zhang, Yali Zhou, Jianguo Yan · 2023 · Neurochemistry International
  74. Crystals in the Substantia Nigra
    Adam Heller, Sheryl S. Coffman · 2019 · ACS Chemical Neuroscience
  75. References
    Christopher A. Shaw · 2017 · Wiley eBooks
  76. Profile of NT-0527, a brain penetrant NLRP3 Inflammasome inhibitor suitable as an in vivo tool compound for neuroinflammatory disorders
    David Harrison, Andy Billinton, Mark G. Bock, Nicholas P. Clarke, Zsofia Digby, Christopher A. Gabel, Nicola A. Lindsay, Valérie Reader, Jane Scanlon, Pamela J. Smolak et al. · 2025 · RSC Medicinal Chemistry
  77. Ester Prodrug NLRP3 Inflammasome Inhibitor NT-0796 is Brain Active due to Activation by Local Expression of Carboxylesterase-1
    Zsofia Digby, Christine Diamond, Heather Wescott, Pamela J. Smolak, Peter Thornton, Nicola A. Lindsay, Christopher A. Gabel, Nicholas P. Clarke, Alan P. Watt · 2026 · ACS Chemical Neuroscience
  78. The effect of AKT inhibition in α-synuclein-dependent neurodegeneration
    Bedri Ranxhi, Zoya R. Bangash, Zachary M. Chbihi, Sokol V. Todi, Peter A. LeWitt, Wei‐Ling Tsou · 2025 · Frontiers in Molecular Neuroscience
  79. Age-associated diseases: the role of the inflammasome complex
    Ludmila V. Gankovskaya, O.V. Artemyeva, Греченко Вячеслав Владимирович, Насаева Екатерина Дмитриевна, Е. М. Хасанова · 2023 · Immunologiya
  80. The potential role of CGRP in synuclein-associated neurodegenerative disorders
    Athanasia Alexoudi, Vincenzo Donadio, Elissaios Karageorgiou · 2024 · Frontiers in Neuroscience
  81. hCeO2@CA-074Me Nanoparticles Alleviate Inflammation and Improve Osteogenic Microenvironment by Regulating the CTSB-NLRP3 Signaling Pathway
    Zhaojun Niu, Xiaomin Xia, Zhimin Zhang, Jie Liu, Xue Li · 2025 · International Journal of Nanomedicine · Retracted
  82. Neuropharmacological Interventions of Plant Origin for Parkinson's Disease: A Comprehensive Appraisal
    Umar Muzaffer, Bisma Gull, Zabeer Ahmed, Muzamil Ahmad · 2025 · Current Neuropharmacology
  83. C-Reactive Protein and Neurodegenerative Diseases
    Inês Lopes Cardoso, Maria Fernanda C. Leal · 2020 · Springer eBooks
  84. Current and future clinical utilities of Parkinson’s disease and dementia biomarkers: can they help us conquer the disease?
    Gilbert J. Ho, Yoshiki Takamatsu, Masaaki Waragai, Ryoko Wada, Shuei Sugama, Takato Takenouchi, Masayo Fujita, Alysha Ali, Mindy Hsin-I Hsieh, Makoto Hashimoto · 2019 · Expert Review of Neurotherapeutics
  85. Unraveling Neurodegeneration: Common Molecular Mechanisms and Novel Therapeutic Concepts in Major Neurodegenerative Disorders
    Fatemeh sadat Aldaghi, Zakieh Siahpoosh, Zivar Salehi, Farhad Mashayekhi, Sh. Sohrabnezhad · 2026 · Brain and Behavior
  86. Emerging targets signaling for inflammation in Parkinson’s disease drug discovery
    Rhema Chandan Khairnar, Niraj Parihar, Kedar Sudhir Prabhavalkar, Lokesh Kumar Bhatt · 2022 · Metabolic Brain Disease
  87. Influence of Cigarette Aerosol in Alpha-Synuclein Oligomerization and Cell Viability in SH-SY5Y: Implications for Parkinson’s Disease
    Yuxin Shen, Pe-Shuen Lee, Ming-Chu Teng, Jhih-Hong Huang, Chia C. Wang, Hsiu‐Fang Fan · 2024 · ACS Chemical Neuroscience
  88. The genetic advantage of healthy centenarians: unraveling the central role of NLRP3 in exceptional healthspan
    Stefan F. F. Verlinden · 2024 · Frontiers in Aging
  89. Therapeutic potential of Canna edulis RS3-resistant starch in alleviating neuroinflammation and apoptosis in a Parkinson's disease rat model
    Qian-Kun He, Xueyong Wang, Wei Hu, Jing Cai, Peng Chen, Ming-wei Liu, Yuan-Hua Wu · 2024 · Heliyon
  90. Coronin1A Regulates the Trafficking of Alpha Synuclein in Microglia
    Karl E. Biggs, Emma N. Fikse, Faith L. Anderson, Arminja Nadine Kettenbach, Matthew C. Havrda · 2025 · Journal of Neuroscience
  91. Inflammasome-Mediated Inflammation in Neurodegenerative Diseases
    Jun Young Park, Yeo Wool Kang, Won Gil Cho · 2019 · The Open Neurology Journal
  92. Alpha-synuclein promotes dopaminergic neuron death in Parkinson’s disease through microglial and NLRP3 activation
    Sarah Klein · 2020 · USURJ University of Saskatchewan Undergraduate Research Journal
  93. RETRACTED ARTICLE: Role of TLR2 and TLR4 Signaling in Parkinson’s Disease: An Insight into Associated Therapeutic Potential
    Gagandeep Kaur, Tapan Behl, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Arun Kumar, Sandeep Arora, SIMONA GABRIELA BUNGAU · 2021 · Journal of Molecular Neuroscience · Retracted
  94. How cytosolic compartments play safeguard functions against neuroinflammation and cell death in cerebral ischemia
    Fari Ryan, Seyed Esmaeil Khoshnam, Fariba Khodagholi, Ghorbangol Ashabi, Abolhassan Ahmadiani · 2021 · Metabolic Brain Disease
  95. The Role of Inflammasomes in the Pathogenesis of Neurodegenerative Diseases
    Denis V. Shevchuk, Anna A. Abramova, Mariya N. Zakharova · 2022 · Neurochemical Journal
  96. Potential Impact of Bioactive Compounds as NLRP3 Inflammasome Inhibitors: An Update
    Sonia Kaur Singh, Shiwangi Sharma, Himanshu Sharma · 2024 · Current Pharmaceutical Biotechnology
  97. Sulphonylureas as Adjunct Therapeutic Agents in the Treatment of Autoimmune Conditions: A Narrative Review
    Jasen Elford, Robert J. O’Reilly, Anna‐Marie Babey, Rukshan Ahamed Mohamed Rafeek, Natkunam Ketheesan · 2025 · Pharmacology Research & Perspectives
  98. Negative regulatory mechanisms of NLRP3 inflammasome
    Wei Zhao, Ying QIN · 2018 · Scientia Sinica Vitae
  99. An Overview of Alpha Synuclein Protein and Its Role in Parkinson’s disease
    Zeynep Bengisu Kaya, Pergin Atilla · 2021 · Acta Medica
  100. Inflammaging Targets
    Miriam Capri, Claudio Franceschi, Stefano Salvioli · 2019 · Elsevier eBooks